Net Income

Nova Era Labs promises to revolutionize AI education with virtual labs. But in a market of giants, can it deliver on its bold claims of workforce readiness?

A key regulatory filing reveals First Trust Advisors' major stake in NCC Group, fueling speculation as the UK cybersecurity firm weighs a potential sale.

Emergency rooms are failing kids in crisis. See how one hospital is partnering with community experts to build a faster, more effective path to healing.

The ADA’s new standards push for tech from day one and holistic care, but can the system deliver this innovative future to every patient?

The U.S. Army awards a major contract for the P550 UAS, a modular, AI-driven drone set to revolutionize battlefield intelligence and soldier safety.

75% of employees say pet health impacts their work stress. Discover why pet benefits are no longer a perk, but a key strategy for productivity and talent retention.

The biotech is advancing a promising myelofibrosis therapy while developing a next-gen 'super drug,' a dual strategy signaling significant growth.

A South Korean biotech's novel antibody, now named rapaprutug, could shift the paradigm for pulmonary arterial hypertension by targeting its root causes.

Sana Biotech’s new data shows it can edit stem cells directly in the body, a potential game-changer for blood disorders and a challenge to current therapies.

As the aging U.S. grid strains under explosive demand, industrial leaders are turning to microgrids for energy independence and financial stability.

A sleepy cat GIF with 2.4B views is now a children's book. We analyze the business strategy behind turning viral fame into a publishing success story.

SS Innovations is betting its cost-efficient SSi Mantra robot can break into the U.S. market. Will affordability democratize the operating room?

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

A new clinical trial in Malaysia could democratize advanced cancer care, testing an affordable, donor-derived immunotherapy challenging costly personalized treatments.

In a stunning strategic shift, Transcontinental sells its largest division to ProAmpac, rewarding shareholders and refocusing on its printing roots.

As CEO J.K. Symancyk prepares for a key investor conference, Signet Jewelers' new strategy faces the test of a market transformed by tech and ethics.

A new Solana meme coin is turning failure into a feature, offering tokens to traders for their verified losses. Is it a gimmick or the future of engagement?

Amid a CEO change, Sherritt International faces a pivotal moment. Can a new leader steer its vital nickel and cobalt assets through volatile markets?

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.